Surrozen, Inc.
SRZN
Positions held
Your positionsSRZN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $328.75M | Enterprise value | $233.02M | Trailing P/E | — | Forward P/E | -6.68 |
| PEG | — | Price / book | -1.50 | Beta | 0.47 | Dividend yield | 0.00% |
| Revenue growth | 4.1% | Earnings growth | — | Gross margin | -2.0% | Operating margin | -2.1% |
| Profit margin | 0.0% | ROE | — | ROA | -25.4% | Debt / equity | — |
| Current ratio | 12.14 | Free cash flow | -$21.75M | Analyst recommendation | strong_buy | Mean target | $48.40 |
| 52w high | $37.83 | 52w low | $11.39 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.0M | $5.0M | $0.5M | $1.0M | $1.0M | — |
| Op margin | -207.4% | -209.1% | -2393.8% | -1107.3% | -917.3% | — |
| Net income | $50.2M | -$128M | -$183M | -$71.6M | $39.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.4M | -$10.5M | -$12.6M | -$10.9M | -$9.0M | — |
- Revenue +0% vs prior quarter ($5.0M vs $5.0M).
- Operating margin expanded to -207.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.5M | $10.7M | $0.0M | $12.5M |
| Op margin | -1210.6% | -239.7% | — | -354.7% |
| Net income | -$242M | -$63.6M | -$43.0M | -$36.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$42.1M | -$25.5M | -$43.0M | -$44.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Surrozen secures FDA clearance for SZN-8141 clinical trial
2026-10-02 · Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance
2026-10-02 · Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-09-08 · Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema
2026-09-08 · Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-09-02 · Surrozen to Present at Upcoming Healthcare Investor Conferences
2026-08-20 · William Blair Initiates Surrozen at Outperform
2026-08-06 · Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-22 · Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Price (daily)
Full chart · RSI · MACD · patterns